Market Overview

Novartis Announces Secukinumab Demonstrated Superiority to Enbrel

Novartis (NYSE: NVS) announced today top-line results from the head-to-head Phase III psoriasis study which showed the superiority of secukinumab (AIN457) in clearing skin to EnbrelĀ®* (etanercept), an anti-tumor necrosis factor (anti-TNF) therapy. In addition, secukinumab (AIN457) met all primary and secondary endpoints. The FIXTURE trial (the Full year Investigative eXamination of secukinumab vs. eTanercept Using 2 dosing Regimens to determine Efficacy in psoriasis) was a randomized, double-blind, double-dummy, placebo-controlled, multicenter global study of subcutaneous secukinumab (AIN457) in moderate-to-severe plaque psoriasis involving 1,307 patients. It was designed to demonstrate efficacy after 12 weeks of treatment, compared to placebo and etanercept, and to assess the safety, tolerability and long-term efficacy

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (NVS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free